Article in Circulation. Genomic and precision medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors.
Robin M PerelliDepartment of Cell Biology (R.M.P., C.A.G., A.P.L.), Duke University, Durham, NC.ORCID 0000-0002-5120-0470
Madeleine J SittonDepartment of Biomedical Engineering (M.J.S., J.D.B., A.P.-O., K.T.M.C., H.D., A.A., C.A.G.), Duke University, Durham, NC.ORCID 0000-0002-3275-9105
Joel D BohningDepartment of Biomedical Engineering (M.J.S., J.D.B., A.P.-O., K.T.M.C., H.D., A.A., C.A.G.), Duke University, Durham, NC.ORCID 0009-0004-4046-5344
Adrian Pickar-OliverDepartment of Biomedical Engineering (M.J.S., J.D.B., A.P.-O., K.T.M.C., H.D., A.A., C.A.G.), Duke University, Durham, NC.ORCID 0000-0001-8160-2158
K Tyler McCulloughDepartment of Biomedical Engineering (M.J.S., J.D.B., A.P.-O., K.T.M.C., H.D., A.A., C.A.G.), Duke University, Durham, NC.
Mary E Moya-MendezDepartment of Pediatrics, Division of Pediatric Cardiology (M.E.M.-M., S.Z., A.P.L.), Duke University, Durham, NC.ORCID 0000-0003-0845-6750
Scott ZhengDepartment of Pediatrics, Division of Pediatric Cardiology (M.E.M.-M., S.Z., A.P.L.), Duke University, Durham, NC.
Heather DanielsDepartment of Biomedical Engineering (M.J.S., J.D.B., A.P.-O., K.T.M.C., H.D., A.A., C.A.G.), Duke University, Durham, NC.ORCID 0009-0004-7857-5127
Garth DevlinDepartment of Surgery (G.D., A.A., C.A.G.), Duke University, Durham, NC.
Aravind AsokanDepartment of Biomedical Engineering (M.J.S., J.D.B., A.P.-O., K.T.M.C., H.D., A.A., C.A.G.), Duke University, Durham, NC.ORCID 0000-0001-5563-4877
Charles A GersbachDepartment of Cell Biology (R.M.P., C.A.G., A.P.L.), Duke University, Durham, NC.ORCID 0000-0003-1478-4013
Andrew P LandstromDepartment of Cell Biology (R.M.P., C.A.G., A.P.L.), Duke University, Durham, NC.ORCID 0000-0002-1878-9631
Funding
University Training Program in Biomolecular & Tissue EngineeringT32GM008555 · NIGMS · DUKE UNIVERSITY · PI GERSBACH, CHARLES A. · 1994 to 2021
$8.1M
Exploring the role of ATP1A3 mutations in sudden unexplained death in epilepsyR01HL160654 · NHLBI · DUKE UNIVERSITY · PI Andrew P. Landstrom · 2022 to 2026
$3.4M
Determining the genetic and social determinants of heart failure and mortality in patients with congenital heart disease (DEFINE)R01HL166217 · NHLBI · DUKE UNIVERSITY · PI Andrew P. Landstrom · 2023 to 2026
$2.8M
University Training Program in Biomolecular and Tissue EngineeringT32GM144291 · NIGMS · DUKE UNIVERSITY · PI Charles A. Gersbach, Tatiana Segura · 2022 to 2026
$2.6M
Evolving High Potency AAV Vectors for Neuromuscular Genome EditingUH3AR075336 · NIAMS · DUKE UNIVERSITY · PI ASOKAN, ARAVIND · 2021 to 2022
$2.0M
CRISPR/Cas9-Based Gene Editing for the Correction of Duchenne Muscular DystrophyR01AR069085 · NIAMS · DUKE UNIVERSITY · PI GERSBACH, CHARLES A. · 2016 to 2020
$1.7M
Microphysiological Human Tissue Systems for Monitoring of Genome Editing OutcomesU01EB028901 · NIBIB · DUKE UNIVERSITY · PI BURSAC, NENAD, GERSBACH, CHARLES A. · 2019 to 2019
$668k
Gene Therapy for the Treatment of Neurofibromatosis Type I (NF1)F99CA274707 · NCI · DUKE UNIVERSITY · PI SITTON, MADELEINE JANETTE · 2022 to 2023
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Deletion of Exon 51 in a Humanized Duchenne Muscular Dystrophy Mouse Model Abolishes Ventricular Arrhythmia Predisposition. · full record | OpenQuestion